UTAA06 Injection for Treatment of Advanced Malignant Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 5, 2023

Primary Completion Date

May 8, 2025

Study Completion Date

May 8, 2025

Conditions
Conditions or Focus of Study: B7-H3 Positive Relapsed/Advanced Malignant Solid Tumor
Interventions
BIOLOGICAL

UTAA06 injection for treatment of advanced malignant solid tumors

The subjects who sign the informed consent forms and been screened by inclusion/exclusion criteria,will be assigned into 1×10\^8CAR+gdT、3×10\^8CAR+gdT、5×10\^8CAR+gdT、8×10\^8CAR+gdT、1×10\^9CAR+gdT groups inder of sequence.And the subjects will be administered once.

Trial Locations (1)

230088

PersonGen Anke Cellular Therapeutice Co.,Ltd, Hefei

All Listed Sponsors
lead

Peking University

OTHER

NCT06372236 - UTAA06 Injection for Treatment of Advanced Malignant Solid Tumors | Biotech Hunter | Biotech Hunter